Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287984 | 0.86 | RAB9A (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10206745 | 0.84 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15396125 | 0.82 | BMP1 (0.47) | TAS2R14 | |
| SCHEMBL15387884 | 0.80 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287925 | 0.79 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287372 | 0.75 | RAB9A (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287283 | 0.74 | MEN1 (0.59) | TAS2R14MEN1KMT2ACXCR3POLB | |
| SCHEMBL1287505 | 0.72 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16004949 | 0.70 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1287498 | 0.70 | MEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310384-A1 | Sulfonamide-Containing Compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | BACE1, BACE2, GSAP | PSEN1 4/4885PSEN2 5/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.